ArticleNature communications2024
The genomic and transcriptomic landscape of metastastic urothelial cancer.
Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Relationship Among DNA Damage Response Gene Alterations, Molecular Subtypes, and Survival Outcomes in Patients With Metastatic Bladder Cancer Treated on CALGB 90601.JCO precision oncology · 2025Trial
- Article
- OncogenicJournal for immunotherapy of cancer · 2026Article
- Cancer Heterogeneity and Cancer Cell Plasticity: Molecular Mechanisms and Precision Therapy.MedComm · 2026Review
- High Sensitivity ctDNA Analysis Using a Novel Panel and NOIR-SS Technology for Monitoring Advanced Urothelial Carcinoma.Cancer medicine · 2026Article
- Comparative genomic landscape of primary and metastatic bladder urothelial carcinoma in a large-scale cohort.International journal of clinical oncology · 2026Article
- Molecular subtype concordance and metastatic patterns in muscle-invasive bladder cancer.The journal of pathology. Clinical research · 2026Article
- Bioinformatics profiling of NECTIN4 in lung cancer and comparative evaluation of NECTIN4-targeted ⁶⁸Ga-N188 and ¹⁸F-FDG PET/CT.Journal of translational medicine · 2026Article
- Cell-of-origin and genetic drivers define advanced bladder cancer subtypes and potential therapeutic response in mouse models.Journal of experimental & clinical cancer research : CR · 2026Article
- Mechanisms and implications of epithelial cell plasticity in the bladder.Nature reviews. Urology · 2026Review
- Metastatic extramammary Paget's disease successfully treated by trastuzumab deruxtecan: a rare case report.Frontiers in medicine · 2026Article
- Exosomal TACSTD2 promotes invasion, metastasis and glycolysis in ovarian cancer.Discover oncology · 2025Article
- Exploratory analysis of the molecular and genomic landscape of upper tract urothelial carcinoma using long-read sequencing.BMC cancer · 2025Article
- Factors associated with primary resistance to enfortumab vedotin in previously treated patients with metastatic urothelial carcinoma: a multicenter retrospective study.International journal of clinical oncology · 2025Article
- Genomics guiding personalized first-line immunotherapy response in lung and bladder tumors.Journal of translational medicine · 2025Article
- Use of 3' Rapid Amplification of cDNA Ends (3' RACE)-Based Targeted RNA Sequencing for Profiling of Druggable Genetic Alterations in Urothelial Carcinomas.International journal of molecular sciences · 2024Article
- Tumor-shrinking effects of enfortumab vedotin between primary urothelial carcinoma and metastatic organs.Frontiers in oncology · 2024Article
Corrections and comments
- Erratum issued
Authors and funding
31 authors.
Funding
Abstract
Metastatic urothelial carcinoma (mUC) is a lethal cancer, with limited therapeutic options. Large-scale studies in early settings provided critical insights into the genomic and transcriptomic characteristics of non-metastatic UC. The genomic landscape of mUC remains however unclear. Using Whole Exome (WES) and mRNA sequencing (RNA-seq) performed on metastatic biopsies from 111 patients, we show that driver genomic alterations from mUC were comparable to primary UC (TCGA data). APOBEC, platin, and HRD mutational signatures are the most prevalent in mUC, identified in 56%, 14%, and 9% of mUC samples, respectively. Molecular subtyping using consensus transcriptomic classification in mUC shows enrichment in neuroendocrine subtype. Paired samples analysis reveals subtype heterogeneity and temporal evolution. We identify potential therapeutic targets in 73% of mUC patients, of which FGFR3 (26%), ERBB2 (7%), TSC1 (7%), and PIK3CA (13%) are the most common. NECTIN4 and TACSTD2 are highly expressed regardless of molecular subtypes, FGFR3 alterations and sites of metastases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.